Thu 09/30/2021 09:08 AM
Share this article:
Direct lenders and sponsors are competing to back the sale of French producer of pharmaceutical hyaluronic acid HTL Biotechnology, which has been marketed off EBITDA of about €50 million and is expecting valuation multiples as high as 20x to 30x, sources told Reorg.

The company’s existing lenders include Arcmont, Barings, Bridgepoint and Eurazeo Private Debt, sources said. Some of these lenders are considering providing debt at 8x leverage including a unitranche at 7x and PIK
Share this article:
This article is an example of the content you may receive if you subscribe to a product of Reorg Research, Inc. or one of its affiliates (collectively, “Reorg”). The information contained herein should not be construed as legal, investment, accounting or other professional services advice on any subject. Reorg, its affiliates, officers, directors, partners and employees expressly disclaim all liability in respect to actions taken or not taken based on any or all the contents of this publication. Copyright © 2021 Reorg Research, Inc. All rights reserved.
Thank you for signing up
for Reorg on the Record!